Dronedarone: An overview

Annals of Medicine

Volumn 44, Issue 1, 2012, Pages 60-72

  Kozlowski, Dariusz ^a   Budrejko, Szymon ^a   Lip, Gregory Y H ^b   Mikhailidis, Dimitri P ^c   Rysz, Jacek ^d   Raczak, Grzegorz ^a   Banach, MacIej ^d  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Amiodarone; atrial fibrillation; dronedarone; SR33589

Indexed keywords

AMIODARONE; CREATININE; DIGOXIN; DRONEDARONE; LIOTHYRONINE; PLACEBO; THYROXINE;

BRADYCARDIA; CARDIOVASCULAR RISK; CARDIOVERSION; CREATININE BLOOD LEVEL; DIARRHEA; DIGOXIN BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; EYE DISEASE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROARRHYTHMIA; HEART RATE; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY INJURY; LIVER DISEASE; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; LUNG FIBROSIS; MEDLINE; MORTALITY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RECURRENCE RISK; RESPIRATORY FUNCTION; REVIEW; SIDE EFFECT; SINUS RHYTHM; SKIN DISEASE; STROKE; SUPRAVENTRICULAR TACHYCARDIA; THYROID DISEASE; THYROID FUNCTION; TORSADE DES POINTES; VISION; VOMITING;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; HEART RATE; HOSPITALIZATION; HUMANS; TREATMENT OUTCOME;

EID: 84856247478     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.594808     Document Type: Review

References (43)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:651-745. (Pubitemid 44472247)
2. Aronow WS, Banach M. Atrial fibrillation: the new epidemic of the ageing world. J Atrial Fibrillation. 2009;1:337-61.
3. Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at' moderate risk' [CHADS2 score = 1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost. 2010;103:683-5.
4. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. (Pubitemid 35417773)
5. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40. (Pubitemid 35417774)
6. Freudenberger RS, Wilson AC, Kostis JB; AFFIRM Investigators and Committees. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol. 2007;100:247-52. (Pubitemid 47042000)
7. Guglin M, Chen R, Curtis AB. Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial. Heart Rhythm. 2010;7:596-601.
8. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-13. (Pubitemid 38420179)
9. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781-8.
10. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719-28.
11. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:746-837.
12. Kozlowski D, Budrejko S, Lip GYH, Mikhailidis DP, Rysz J, Raczak G, et al. Vernakalant hydrochloride for the treatment of atrial fibrillation. Expert Opin Investig Drugs. 2009;18:1929-37.
13. Kowalczyk M, Banach M, Lip GYH, Kozł owski D, Mikhailidis DP, Rysz J. Levosimendan-a calcium sensitising agent with potential anti-arrhythmic properties. Int J Clin Pract. 2010;64:1148-54.
14. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357:987-99. (Pubitemid 47367078)
15. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24: 1481-7. (Pubitemid 37010577)
16. Dronedarone: drondarone, SR 33589, SR 33589B. Drugs R D. 2007;8:171-5.
17. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol. 1995;279:25-32.
18. Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today (Barc). 2006;42:75-86.
19. Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs. 2004;13:415-26. (Pubitemid 38489530)
20. Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol. 1995;116: 1949-56.
21. Finance O, Manning A, Chatelain P. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol. 1995;26:570-6.
22. (Pubitemid 40637636)
23. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358:2678-87. (Pubitemid 351860860)
24. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64: 785-91. (Pubitemid 350222063)
25. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360:668-78.
26. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J. 2010;31:1717-21.
27. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174-80.
28. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156: 527.e1-9.
29. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol. 2010;21:597-605.
30. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54: 1089-95.
31. Varro A, Takacs J, Nemeth M, Hala O, Virag L, Iost N, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol. 2001;133: 625-34. (Pubitemid 32642867)
32. Manning A, Thisse V, Hodeige D, Richard J, Heyndrickx JP, Chatelain P. SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol. 1995;25:252-61.
33. Cooper JA. Dronedarone is superior to placebo the case for optimism. J Am Coll Cardiol. 2010;55:1052.
34. Lewalter T. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2010;55: 1051-2.
35. Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med. 2005;165:1185-91. (Pubitemid 40723655)
36. Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, et al. Postoperative atrial fibrillation-what do we really know? Curr Vasc Pharmacol. 2010;8:553-72.
37. Duray GZ, Schmitt J, Hohnloser SH. Dronedarone therapy in atrial fibrillation: A summary of recent controlled trials. J Cardiovasc Pharmacol Ther. 2010;15(4 Suppl): 19S-23S.
38. Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol. 2003;41:191-202. (Pubitemid 36135243)
39. + current in guinea pig atrial cells. J Cardiovasc Pharmacol. 2000;36:802-5.
40. Burashnikov A, Belardinelli L, Antzelevitch C. Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm. 2010;7:1273-9.
41. Aimond F, Beck L, Gautier P, Cherif OK, Davy JM, Lorente P, et al. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J Pharmacol Exp Ther. 2000;292:415-24. (Pubitemid 30026401)
42. Manning AS, Bruyninckx C, Ramboux J, Chatelain P. SR 33589, a new amiodarone-like agent: effect on ischemia-and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol. 1995;26:453-61.
43. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999;100:2276-81.